Diagnostic Testing for Invasive Pulmonary Aspergillosis
To rule out invasive pulmonary aspergillosis, obtain a chest CT scan immediately, perform bronchoscopy with bronchoalveolar lavage (BAL) for galactomannan testing and fungal culture, and send serum galactomannan—these tests in combination provide the highest diagnostic accuracy. 1, 2
Algorithmic Diagnostic Approach
Step 1: Imaging
- Obtain chest CT scan without delay when clinical suspicion exists, regardless of chest X-ray results 2
- Contrast is NOT routinely needed unless a nodule/mass is adjacent to large vessels 2
- Key CT findings suggesting aspergillosis:
Step 2: Bronchoscopy with BAL (Highest Yield)
Perform bronchoscopy with BAL unless contraindicated by severe hypoxemia, bleeding risk, or platelet transfusion-refractory thrombocytopenia 2
Send BAL fluid for:
- Galactomannan testing (sensitivity 85.5%, specificity 82.9%—the single most accurate test) 1, 4
- Fungal culture (high volume)
- Direct microscopy for fungi
- Aspergillus PCR (when combined with BAL GM, sensitivity 64.4%, specificity 80%) 5, 4
Step 3: Serum Testing
- Serum galactomannan: Recommended in high-risk patients (hematologic malignancy, neutropenia, transplant recipients) 1, 2
- Serum β-D-glucan: Can support diagnosis but is NOT specific for Aspergillus (detects multiple fungi) 2
- Aspergillus IgG antibody: Most useful for chronic forms, not acute invasive disease 2
Step 4: Risk Stratification
The diagnostic approach varies by patient population:
High-risk immunocompromised patients (hematologic malignancy, neutropenia, HSCT):
COPD patients with exacerbation (if ≥2 risk factors: systemic/high-dose inhaled steroids, bronchiectasis, diabetes, prolonged antibiotics):
- Respiratory sample (sputum/induced sputum/BAL) for microscopy, culture, PCR, and GM
- Serum GM and Aspergillus IgG
- Chest CT
- Diagnosis requires: high-risk patient + compatible imaging + any two positive Aspergillus tests 5
Critically ill/ICU patients (including post-viral infections like influenza or COVID-19):
- BAL GM, fungal culture, and Aspergillus PCR
- Bronchoscopy to visualize invasive Aspergillus tracheobronchitis 6, 4
Clinical Symptoms to Recognize
Common Presenting Symptoms (in order of frequency):
- Cough (50-58% of cases) 7, 8
- Sputum production (32-37%) 7
- Fever and chills 8
- Shortness of breath/dyspnea (23%) 7
- Hemoptysis (blood in sputum, 23%) 7
- Pleuritic chest pain (6-7%) 3, 7
Important Clinical Pitfalls:
- Symptoms are nonspecific and can mimic tuberculosis, bacterial pneumonia, or other infections 3, 9
- Cough and increased respiratory rate appear before abnormal lung sounds on examination 8
- In immunocompetent patients, maintain high suspicion even without classic risk factors 3
- Hemoptysis is a late finding and indicates advanced disease 7
Systemic Manifestations:
- Weight loss and fatigue (particularly in chronic forms) 2
- Progressive respiratory decline
- Persistent fever despite antibiotics
Critical Timing Considerations
Early diagnosis is paramount: Delayed diagnosis significantly increases mortality 9, 4. The interval from ICU admission to first positive mycological test independently predicts death (HR 1.017 per day delay) 4.
Initiate antifungal therapy immediately when suspicion is strong, even while diagnostic workup is ongoing 2. Mortality rates exceed 50-55% in ICU patients with invasive aspergillosis despite treatment 6, 4.
Key Diagnostic Caveats
- PCR testing: Use cautiously on case-by-case basis; interpret in conjunction with other tests and clinical context 2
- False-positive serum GM: Can occur with chemotherapy, mucositis, or cross-reactive epitopes from other organisms—use BAL GM for confirmation 1
- Peripheral nodular lesions: BAL has low yield; consider percutaneous or endobronchial biopsy 2
- Patients on antifungal prophylaxis: Serum GM not recommended for screening, but BAL GM remains useful 2